COST-EFFECTIVNESS ANALYSIS OF AXITINIB IN THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA – CLINICAL DATA VS RWE

Author(s)

Karbusicka M1, Losenicky L2, Mazan P2, Doleckova J1, Duba J1, Kolek M1
1OAKS Consulting s.r.o., Prague 9, Czech Republic, 2Pfizer PFE, spol. s r.o., Prague 5, Czech Republic

OBJECTIVES:  The aim was to compare costs and effectiveness of axitinib against everolimus in the treatment of metastatic renal cell carcinoma (mRCC) in sunitinib refractory patients from the perspective of the public healthcare payer in the Czech Republic. METHODS:  A Markov model was developed to estimate the incremental cost per incremental quality-adjusted life year (QALY) gained of axitinib compared to everolimus in the treatment of mRCC in sunitinib refractory patients over a 10-year time horizon. Progression-free survival (PFS) and overall survival (OS) were selected as basic parameters of effectiveness. PFS and OS were calculated using parametric survival distributions estimated from Kaplan-Meier curves. As no head-to-head trials comparing axitinib and everolimus in treatment of mRCC in sunitinib refractory patients were found, three different approaches are shown: a naive approach comparing data from AXIS and RECORD trials, matching-adjusted indirect comparison (MAIC) comparing real world data for axitinib from Czech registry and clinical trial data for everolimus (RECORD trial) and Simulated Treatment Comparison of AXIS and RECORD trials. Among relevant costs (reflecting payer’s perspective) drug costs, monitoring costs and cost of adverse events were considered. RESULTS:  In the naive comparison scenario axitinib is dominant compared to everolimus as it is less costly and generates more QALY. When using Czech real world evidence (RWE) and RECORD trial the incremental cost-effectiveness ratio (ICER) of axitinib reached 24,089.71 EUR per QALY gained. The last scenario (STC of AXIS and RECORD) the ICER was 23,000.43 EUR. All of the three scenarios scored way under the level of Czech willingness to pay (WTP) 43,584.06 EUR. CONCLUSIONS:  Axitinib proved efficacy in the real clinical practice in the Czech Republic. The cost-effectiveness analysis also showed that axitinib can be considered a cost-effective treatment for mRCC sunitinib refractory patients when compared to everolimus.

Conference/Value in Health Info

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PCN156

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Oncology

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×